Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0961203317703495 http://scihub22266oqcxt.onion/10.1177/0961203317703495 C5673008!5673008 !28467293     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28467293 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 276.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28467293 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Lupus 2017 ; 26 (14 ): 1483-1490 Nephropedia Template TP {{tp|p=28467293 |t=2017. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus |pdf=|usr=}}{{28467293 }} gab.com Text A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus JO: Lupus http://www.kidney.de/pget.php?&tw=1&pmid=28467293 #FOAvip Objective Intravenous belimumab 10?mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10?mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy. Analyses of vaccine titers were performed on the as-treated population (received ?1 dose of belimumab). The primary endpoint was the proportion of patients with positive antibody responses (?2-fold increase from pre-vaccination levels, or post-vaccination level???0.6?µg/mL if pre-vaccination levels were unquantifiable) to ?1 of 23 pneumococcal vaccine serotypes, four weeks post vaccination. Other endpoints included the proportion of patients with positive antibody responses to ?2 to ?10, and ?11-23 (post hoc analysis) of serotypes. Safety was assessed by monitoring adverse events. Results Seventy-nine patients received pneumococcal vaccination (pre-belimumab cohort, n?=?34; belimumab-concurrent cohort, n?=?45). The majority (87.3% [69/79]) completed the study; 10 (12.7%) withdrew (patient request, n?=?3; adverse event, n?=?3; lost to follow-up, n?=?2; other, n?=?2). At Week 4 post-vaccination, 97.0% (32/33) and 97.6% (40/41) of patients (pre-belimumab and concurrent belimumab cohorts, respectively) had a positive response to ?1 of 23 pneumococcal serotypes. Over 85% of patients in both cohorts responded to ?10 of serotypes, approximately 80% responded to ?12 serotypes, and approximately two-thirds responded to ?16 serotypes. Little difference was observed between cohorts across a broad response, up to 23 serotypes. Eight (23.5%) patients experienced an adverse event considered by the investigator to be treatment-related in the pre-belimumab cohort and four (8.9%) in the belimumab-concurrent cohort; seven patients experienced non-fatal serious adverse events (pre-belimumab cohort, 11.8% [ n?=?4]; concurrent-belimumab cohort, 6.7% [ n?=?3]), and no deaths were reported. Conclusion The proportion of patients generating a response to ?1 pneumococcal serotype did not differ between the pre-belimumab and belimumab-concurrent cohorts; the proportions were also comparable across a broader response (from ?2 serotypes to 23 serotypes). Twit Text FOAVip A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus ????Lupus http://www.kidney.de/pget.php?&tw=1&pmid=28467293 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28467293 #FOAvip English Wikipedia <ref>{{Cite pmid|28467293 }}</ref> A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus #MMPMID28467293 Chatham W ; Chadha A ; Fettiplace J ; Kleoudis C ; Bass D ; Roth D ; Gordon D Lupus 2017[Dec]; 26 (14 ): 1483-1490 PMID28467293 show ga Objective Intravenous belimumab 10?mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10?mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy. Analyses of vaccine titers were performed on the as-treated population (received ?1 dose of belimumab). The primary endpoint was the proportion of patients with positive antibody responses (?2-fold increase from pre-vaccination levels, or post-vaccination level???0.6?µg/mL if pre-vaccination levels were unquantifiable) to ?1 of 23 pneumococcal vaccine serotypes, four weeks post vaccination. Other endpoints included the proportion of patients with positive antibody responses to ?2 to ?10, and ?11-23 (post hoc analysis) of serotypes. Safety was assessed by monitoring adverse events. Results Seventy-nine patients received pneumococcal vaccination (pre-belimumab cohort, n?=?34; belimumab-concurrent cohort, n?=?45). The majority (87.3% [69/79]) completed the study; 10 (12.7%) withdrew (patient request, n?=?3; adverse event, n?=?3; lost to follow-up, n?=?2; other, n?=?2). At Week 4 post-vaccination, 97.0% (32/33) and 97.6% (40/41) of patients (pre-belimumab and concurrent belimumab cohorts, respectively) had a positive response to ?1 of 23 pneumococcal serotypes. Over 85% of patients in both cohorts responded to ?10 of serotypes, approximately 80% responded to ?12 serotypes, and approximately two-thirds responded to ?16 serotypes. Little difference was observed between cohorts across a broad response, up to 23 serotypes. Eight (23.5%) patients experienced an adverse event considered by the investigator to be treatment-related in the pre-belimumab cohort and four (8.9%) in the belimumab-concurrent cohort; seven patients experienced non-fatal serious adverse events (pre-belimumab cohort, 11.8% [ n?=?4]; concurrent-belimumab cohort, 6.7% [ n?=?3]), and no deaths were reported. Conclusion The proportion of patients generating a response to ?1 pneumococcal serotype did not differ between the pre-belimumab and belimumab-concurrent cohorts; the proportions were also comparable across a broader response (from ?2 serotypes to 23 serotypes). |Adult [MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage/adverse effects [MESH] |Antibody Formation/immunology [MESH] |Autoantibodies/immunology [MESH] |Female [MESH] |Humans [MESH] |Immunosuppressive Agents/*administration & dosage/adverse effects [MESH] |Lupus Erythematosus, Systemic/*drug therapy/immunology [MESH] |Male [MESH] |Middle Aged [MESH] |Pneumococcal Vaccines/*administration & dosage/immunology [MESH] |Serogroup [MESH]A randomized, open-label study to investigate the effect of belimumab (epmc).pdf DeepDyve Pubget Overpricing